Abstract 1473P
Background
Biological sex and gender has an impact on the incidence rate and outcome in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). The aim of this study is to describe patient characteristics, treatment allocation and overall survival (OS) among men and women with mPDAC in a nationwide cohort.
Methods
Patients with synchronous mPDAC diagnosed between 2015 and 2019 were selected from the Netherlands Cancer Registry (NCR). The association between gender and the probability of receiving systemic treatment was examined with multivariable logistic regression analyses. Kaplan Meier analyses with log-rank test were used to describe median OS.
Results
A total of 7470 patients with mPDAC were included in this study. The majority of patients was male (52%) with a median age of 71 (IQR 63-78). Among all patients, more men received systemic treatment compared to women (54% vs. 46%, P=0.002). Multivariable logistic regression analyses with adjustment for gender, age, comorbidity, performance status, year of diagnosis and number of metastatic locations showed that female gender at ≤55 years of age, was statistically significant associated with a higher probability of receiving systemic treatment (OR 1.82, 95% CI 1.24-2.68). In contrast, female gender at >55 years of age had a statistically significantly lower probability of receiving systemic treatment (OR, 0.85 95% CI 0.76-0.96). Median OS was significantly higher in women >55 years of age with and without the administration of systemic treatment (P=0.04 for both).
Conclusions
This real-world study is the first to provide information about the impact of gender on treatment allocation and survival in patients with mPDAC. Younger women (≤55 years) have a higher probability to receive systemic treatment compared to men. Older women (>55 years) have better median overall survival compared to men.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding
Disclosure
A.D. Wagner: Financial Interests, Institutional, Other, Travel support for congress participation: AbbVie; Financial Interests, Institutional, Expert Testimony: Daichi Sankyo; Financial Interests, Institutional, Other, Travel support for congress participation: Ipsen; Financial Interests, Institutional, Expert Testimony: Lily; Financial Interests, Institutional, Advisory Board: Merck; Financial Interests, Institutional, Advisory Board: MSD; Financial Interests, Institutional, Advisory Board: Pierre Fabre; Financial Interests, Institutional, Advisory Board: Servier; Non-Financial Interests, Institutional, Research Grant, am coordinating investigator of EORTC 1203, \"INNOVATION\"-trial, which is supported by an educational grant from Roche to EORTC: Roche. J. de vos-Geelen: Financial Interests, Personal and Institutional, Advisory Role: Amgen; Financial Interests, Personal and Institutional, Advisory Role: AstraZeneca; Financial Interests, Personal and Institutional, Advisory Role: MSD; Financial Interests, Personal and Institutional, Advisory Role: Pierre Fabre; Financial Interests, Personal and Institutional, Advisory Role: Servier; Financial Interests, Institutional, Funding: Servier. H. Wilmink: Financial Interests, Personal and Institutional, Advisory Role: Shire; Financial Interests, Personal and Institutional, Advisory Role: Servier; Financial Interests, Personal and Institutional, Advisory Role: Celgene; Financial Interests, Institutional, Research Grant: Servier; Financial Interests, Institutional, Research Grant: Halozyne; Financial Interests, Institutional, Research Grant: Novartis; Financial Interests, Institutional, Research Grant: Celgene; Financial Interests, Institutional, Research Grant: AstraZenica; Financial Interests, Institutional, Research Grant: Pfizer; Financial Interests, Institutional, Research Grant: Roche; Financial Interests, Institutional, Research Grant: Amgen; Financial Interests, Institutional, Research Grant: Merck. H. van Laarhoven: Financial Interests, Personal and Institutional, Advisory Role: BMS; Financial Interests, Personal and Institutional, Advisory Role: Celgene; Financial Interests, Personal and Institutional, Advisory Role: Lilly; Financial Interests, Personal and Institutional, Advisory Role: Merck; Financial Interests, Personal and Institutional, Advisory Role: Nordic; Financial Interests, Personal and Institutional, Advisory Role: Servier; Financial Interests, Institutional, Funding: Bayer; Financial Interests, Institutional, Funding: BMS; Financial Interests, Institutional, Funding: Celgene; Financial Interests, Institutional, Funding: Lilly; Financial Interests, Institutional, Funding: Merck; Financial Interests, Institutional, Funding: Serono; Financial Interests, Institutional, Funding: MSD; Financial Interests, Institutional, Funding: Nordic; Financial Interests, Institutional, Funding: Philips; Financial Interests, Institutional, Funding: Roche; Financial Interests, Institutional, Funding: Servier. All other authors have declared no conflicts of interest.